Skip to main content
. 2005 Jan 14;102(5):1578–1583. doi: 10.1073/pnas.0406808102

Fig. 2.

Fig. 2.

The LC antagonist F991 inhibits the development of mucosal exudation, cellular infiltration, and tracheal hyperreactivity associated with the late phase of DNFB-induced pulmonary hypersensitivity reaction in mice. (a) Immunization with DNFB (black bars) results in an increase in mucosal exudation 24 h after challenge. Intraperitoneal pretreatment with F991 (50 μg per mouse, 24 h and 5 min before challenge) prevented the development of DNFB/DNBS-induced mucosal exudation in the airway lumen. F991 did not influence basal mucosal exudation found in vehicle-sensitized mice; n = 6; *, P < 0.05. (b and d) Tracheal hyperreactivity is found in DNFB-immunized mice (black circle) compared with vehicle-immunized (open circle) mice 24 and 48 h after challenge. (b and d) Injections with F991 blocked the development of tracheal hyperreactivity normally found 24 and 48 h after challenge (c and e); n = 5–6; *, P < 0.05, for the whole curve.